Reubi J C, Schaer J C, Waser B
Division of Cell Biology and Experimental Cancer Research, University of Berne, Switzerland.
Cancer Res. 1997 Apr 1;57(7):1377-86.
Cholecystokinin (CCK)-A and CCK-B/gastrin receptors were evaluated with in vitro receptor autoradiography in 406 human tumors of various origins using a sulfated 125I-labeled CCK decapeptide analogue 125I-(D-Tyr-Gly, Nle28,3l)-CCK 26-33 and 125I-labeled Leu15-gastrin as radioligands. CCK-B/gastrin receptors were found frequently in medullary thyroid carcinomas (92%), in small cell lung cancers (57%), in astrocytomas (65%), and in stromal ovarian cancers (100%). They were found occasionally in gastroenteropancreatic tumors, breast, endometrial, and ovarian adenocarcinomas. They were either not expressed or rarely expressed in colorectal cancers, differentiated thyroid cancers, non-small cell lung cancers, meningiomas, neuroblastomas, schwannomas, glioblastomas, lymphomas, renal cell cancers, prostate carcinomas, and the remaining neuroendocrine tumors (i.e., pituitary adenomas, pheochromocytomas, paragangliomas, and parathyroid adenomas). CCK-A receptors were expressed rarely in tumors except in gastroenteropancreatic tumors (38%), meningiomas (30%), and some neuroblastomas (19%). The identified CCK-A and CCK-B receptors were specific and of high affinity in the subnanomolar range. The rank order of potency of various CCK analogues was: sulfated CCK-8 = L-364,718 >> nonsulfated CCK-8 = L-365,260 > or = gastrin for CCK-A receptors and sulfated CCK-8 > gastrin = nonsulfated CCK-8 > L-365,260 > L-364,718 for CCK-B receptors. CCK-B receptors could also be selectively and specifically labeled with a newly designed nonsulfated 125I-(D-Tyr-Gly, Nle28,31)-CCK 26-33. Gastrin mRNA measured by in situ hybridization was present in most CCK-B receptor-positive small cell lung cancers, breast tumors, and ovarian tumors, representing the molecular basis of a possible autocrine growth regulation of these tumors. Gastrin and CCK mRNAs were lacking in medullary thyroid cancers. Thus, these results may have pathogenic, diagnostic, differential diagnostic, and therapeutic implications.
采用硫酸化的¹²⁵I标记的胆囊收缩素(CCK)十肽类似物¹²⁵I-(D-酪氨酸-甘氨酸,Nle²⁸,³¹)-CCK ²⁶⁻³³和¹²⁵I标记的亮氨酸¹⁵⁻胃泌素作为放射性配体,通过体外受体放射自显影技术对406例不同来源的人类肿瘤中的CCK-A和CCK-B/胃泌素受体进行了评估。CCK-B/胃泌素受体常见于甲状腺髓样癌(92%)、小细胞肺癌(57%)、星形细胞瘤(65%)和卵巢基质癌(100%)。在胃肠胰肿瘤、乳腺癌、子宫内膜癌和卵巢腺癌中偶尔发现。在结直肠癌、分化型甲状腺癌、非小细胞肺癌、脑膜瘤、神经母细胞瘤、神经鞘瘤、胶质母细胞瘤、淋巴瘤、肾细胞癌、前列腺癌以及其余神经内分泌肿瘤(即垂体腺瘤、嗜铬细胞瘤、副神经节瘤和甲状旁腺瘤)中,它们要么不表达,要么很少表达。CCK-A受体除了在胃肠胰肿瘤(38%)、脑膜瘤(30%)和一些神经母细胞瘤(19%)中外,在肿瘤中很少表达。所鉴定的CCK-A和CCK-B受体具有特异性且在亚纳摩尔范围内具有高亲和力。各种CCK类似物的效价顺序为:硫酸化CCK-8 = L-364,718 >> 非硫酸化CCK-8 = L-365,260 ≥ 胃泌素(对于CCK-A受体),以及硫酸化CCK-8 > 胃泌素 = 非硫酸化CCK-8 > L-365,260 > L-364,718(对于CCK-B受体)。CCK-B受体也可以用新设计的非硫酸化¹²⁵I-(D-酪氨酸-甘氨酸,Nle²⁸,³¹)-CCK ²⁶⁻³³进行选择性和特异性标记。通过原位杂交测量的胃泌素mRNA存在于大多数CCK-B受体阳性的小细胞肺癌、乳腺肿瘤和卵巢肿瘤中,这代表了这些肿瘤可能的自分泌生长调节的分子基础。甲状腺髓样癌中缺乏胃泌素和CCK mRNA。因此,这些结果可能具有致病、诊断、鉴别诊断和治疗意义。